08:29 AM EST, 11/14/2024 (MT Newswires) -- ArriVent BioPharma ( AVBP ) reported a Q3 net loss Thursday of $0.61 per diluted share, narrowing from a loss of $5.52 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.82 per share.

As expected, no revenue for the quarter ended Sept. 30 was reported.

As of Sept. 30, the clinical-stage biopharmaceutical company said it had $282.9 million in cash and cash equivalents that could fund operations into 2026.